Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies Inc (TSHA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.4B; returns 1 day -1.1%, 1 week +9.4%, 1 year -19.8%.

Taysha Gene Therapies Inc. (TSHA) is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS). Taysha's primary focus is on advancing its lead product, TSHA-102, currently in a pivotal trial phase, as a potential one-time, disease-modifying treatment for Rett syndrome.

Groups TSHA belongs to

• Gene Therapy
• Rett Syndrome
• Clinical Stage Biotech
• Rare Diseases
• CNS Disorders
• Biotechnology
• Healthcare
• Clinical Stage
• Life Sciences

TSHA financial model: income statement, cash flow and balance sheet